ArticleKidney international reports2026
SGLT2 Inhibitors and Long-Term Outcomes After AKI.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Top ten tips to manage patients after acute kidney injury.Clinical kidney journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Currently, there is no specific treatment for post-acute kidney injury (AKI) survivors, one of the highest risk groups of the renal and nonrenal adverse long-term outcomes. This study aimed to determine whether the sodium-glucose cotransporter-2 inhibitor (SGLT2i) can decrease 1-year major adverse kidney events (MAKE365) in post-AKI setting. Methods: Multicenter randomized controlled trial, involving severe AKI survivors from 3 tertiary care hospitals, who were dialysis independent, and had an estimated glomerular filtration rate (eGFR) ≥ 20 ml/min per 1.73 m Results: A total of 200 participants were included in this study, 98 patients in empagliflozin group and 102 patients in placebo group; AKI stage 3 was predominant, with renal replacement therapy required for 30% and 23% of patients in each group, respectively. On modified intention-to-treat analysis, MAKE365 occurred in 35% in the empagliflozin group and 36% in the placebo group ( Conclusion: Empagliflozin could not show reduction in MAKE365 but showed potential benefits in reducing recurrent AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.